How long does it take for brigatinib to be effective for patients with egfr mutation?

The time for patients with EGFR mutations to take brigatinib to take effect varies depending on individual differences, but the initial effect usually begins to show within 1-2 weeks after treatment. However, to fully evaluate the efficacy of brigatinib, patients generally need to undergo relevant examinations after taking it for 1 month.

Since each patient has different severity of illness, different sensitivity to drugs, and different underlying physical conditions, there are obvious individual differences in the time it takes for brigatinib to take effect. Some patients may feel an improvement in their symptoms within a few days of taking the medication, while others may take longer to see noticeable results.

In clinical practice, brigatinib usually begins to show initial effects within 1-2 weeks after treatment. During this period, patients may notice a reduction in lung cancer-related symptoms such as coughing and difficulty breathing, as well as an improvement in their overall physical condition. However, improvement in these symptoms does not necessarily mean that the tumor has shrunk significantly, but is simply a sign that the drugs are starting to work.

In order to more accurately evaluate the efficacy of brigatinib, doctors usually recommend that patients undergo a CT scan or other imaging examinations after taking it for 1 month. These tests can visually show whether the size and number of tumors have decreased, helping doctors determine whether the drug is effective. If the tumor shrinks significantly or remains stable, then brigatinib is considered effective for the patient.

For patients with EGFR mutationseven if brigatinib shows good efficacy in the short term, continued treatment and regular monitoring of changes in the condition are required. Because lung cancer is a complex disease, various unpredictable situations may occur during its development. Therefore, patients need to insist on taking medication under the guidance of a doctor and undergo relevant examinations regularly to ensure the stability of the condition.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC9820100/